WYE-687
WYE-687[edit | edit source]
WYE-687 is a small molecule inhibitor that targets the mammalian target of rapamycin (mTOR) pathway, which is a critical regulator of cell growth, proliferation, and survival. It is of particular interest in the field of oncology due to its potential to inhibit tumor growth by disrupting the signaling pathways that cancer cells rely on for survival and proliferation.
Mechanism of Action[edit | edit source]
WYE-687 functions by selectively inhibiting the mTOR kinase, which is a component of two distinct complexes: mTORC1 and mTORC2. These complexes play crucial roles in cellular processes such as protein synthesis, autophagy, and metabolism. By inhibiting mTOR, WYE-687 can effectively reduce the phosphorylation of downstream targets such as S6 kinase and 4E-BP1, leading to decreased protein synthesis and cell cycle arrest.
Clinical Applications[edit | edit source]
The inhibition of the mTOR pathway by WYE-687 has shown promise in preclinical studies for the treatment of various types of cancer, including breast cancer, prostate cancer, and glioblastoma. Its ability to target both mTORC1 and mTORC2 makes it a potent agent in overcoming resistance mechanisms that often limit the efficacy of other mTOR inhibitors.
Pharmacokinetics[edit | edit source]
WYE-687 is administered orally and has demonstrated favorable pharmacokinetic properties in animal models. It exhibits good bioavailability and a suitable half-life, making it a candidate for further development in clinical trials.
Side Effects[edit | edit source]
As with other mTOR inhibitors, potential side effects of WYE-687 may include hyperglycemia, hyperlipidemia, and immunosuppression. These effects are due to the broad role of mTOR in regulating metabolic and immune functions.
Research and Development[edit | edit source]
Ongoing research is focused on optimizing the dosing regimens of WYE-687 and evaluating its efficacy in combination with other therapeutic agents. Studies are also exploring its role in overcoming resistance to chemotherapy and targeted therapy in cancer treatment.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
